The Cambridge Probiotic / Antibiotic Trial 2
This double-blind, placebo-controlled study examines the role of probiotic administration in the prevention of C. difficile-associated diarrhoea (CDAD) in elderly patients receiving antibiotic therapy.
Results showed that Lab4 probiotics reduced the incidence of Clostridium difficile diarrhoea in these patients.
46% of patients supplemented with Lab4 probiotics were positive for Clostridium difficile toxin compared to 78% of patients in the placebo group
1. The number of Candida albicans in the Group 1 at the end of antibiotic therapy was significantly higher compared to the Group 2 (*P<0.05).
2. The numbers of facultative anaerobes and enterobacteria were significantly lower in the Group 2 compared to the Group 1 four weeks post antibiotic treatment (*P=0.031 and *P=0.014, respectively)
3. Numbers of patients harbouring antibiotic resistant enterococci increased significantly post antibiotic therapy in the Group 1 (P= 0.012).
4. There was no change in the incidence rate of antibiotic resistance among the patients in the Group 2 post antibiotic therapy.